The Albany Gazette - Exxel Pharma to Participate in a "New to Virtual Investor" Segment

NYSE - LSE

GSK	-0.32%	47.03	$
CMSC	0.4%	20.24	$
RIO	1.42%	94.21	$
RBGPF	0.14%	65.09	$
AZN	-0.51%	156.9	$
BTI	0.54%	52.64	$
BCE	-0.96%	19.73	$
NGG	1.04%	76.12	$
CMSD	0.44%	20.43	$
BCC	0.39%	74.99	$
RYCEF	0.62%	19.42	$
VOD	2.62%	16.82	$
RELX	-0.21%	33.42	$
BP	0.65%	44.79	$
JRI	1.19%	10.9	$

Exxel Pharma to Participate in a "New to Virtual Investor" Segment

BOULEVARD 31.01.2025

Exxel Pharma to Participate in a "New to Virtual Investor" Segment

Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET

Text size:

AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced that it will participate in a "New to Virtual Investor" segment on Wednesday, February 5, 2025 at 4:00 PM ET.

As part of the event, Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel Pharma, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

A live video webcast will be available on the Investors page of the Company's website (exxelpharma.com). Viewers can also access the event on the Virtual Investor website at virtualinvestorco.com.

About Exxel Pharma

Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity disorders. The Company's lead program, EX937, is a first-in-class, orally administered, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies, EX937 demonstrated robust efficacy in modulating chronic cough across multiple models. Furthermore, it has shown a favorable safety profile and is designed to avoid central side effects by being entirely excluded from the brain. EX937 also holds promise for a range of high-value indications, including hyperactive bladder, peripheral painful neuropathies, and migraine headaches. In addition to EX937, Exxel Pharma is advancing its ARN compounds, a second lead program targeting social anxiety disorder and autism spectrum disorder.

Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
E: [email protected]

SOURCE: Exxel Pharma, Inc.

View the original press release on ACCESS Newswire

(O.Garcia--TAG)

Featured

US prison chief who oversaw botched execution resigns

The prison chief in the southern US state of Tennessee has resigned, the governor said Saturday, after an unprecedented botched execution left a convicted murderer on a ventilator in critical condition.

Turkey football ref chief jailed pending trial for graft

The Turkish Football Federation (TFF) said Saturday it was working to shake up its refereeing oversight body after its top official was jailed pending trial on graft charges.

Man City whistleblower Rui Pinto facing 'dire consequences' - lawyers

Computer hacker Rui Pinto, the man behind the Football Leaks website which helped trigger the Premier League probe into Manchester City's finances, faces "dire consequences" after having his protected witness status removed, his lawyers said on Friday.

Pilot in flydubai attack says could not let 'all those people die'

An Indian pilot attacked by his co-pilot aboard a flight from the UAE to Israel said Friday that he "could not let all those people die", in his first public remarks after he helped stop the plane from crashing.